TY - JOUR
T1 - Expression patterns and bioinformatic analysis of miR-1260a and miR-1274a in Prostate Cancer Tunisian patients
AU - Said, Rahma
AU - Garcia-Mayea, Yoelsis
AU - Trabelsi, Nesrine
AU - Setti Boubaker, Nouha
AU - Mir, Cristina
AU - Blel, Ahlem
AU - Ati, Nidhal
AU - Paciucci, Rosanna
AU - Hernández-Losa, Javier
AU - Rammeh, Soumaya
AU - Derouiche, Amine
AU - Chebil, Mohamed
AU - LLeonart, Matilde E.
AU - Ouerhani, Slah
PY - 2018/12/1
Y1 - 2018/12/1
N2 - © 2018, Springer Nature B.V. Currently, microRNAs (miRs) represent great biomarkers in cancer due to their stability and their potential role in diagnosis, prognosis and therapy. This study aims to evaluate the expression levels of miRs-1260 and -1274a in prostate cancer (PC) samples and to identify their eventual targets by using bioinformatic analysis. In this project, we evaluated the expression status of miRs-1260 and -1274a in 86 PC patients and 19 controls by using real-time quantitative PCR and 2 −ΔΔCt method. Moreover, we retrieved validated and predicted targets of miRs from several datasets by using the “multiMir” R/Bioconductor package. We have found that miRs-1260 and -1274a were over-expressed in PC patients compared to controls (p < 1 × 10 −5 ). Moreover ROC curve for miRs-1260 and 1274a showed a good performance to distinguish between controls group and PC samples with an area under the ROC curve of 0.897 and 0.784 respectively. However, no significant association could be shown between these two miRs and clinical parameters such as PSA levels, Gleason score, tumor stage, D’Amico classification, lymph node metastasis statues, tumor recurrence, metastasis status and progression after a minimum of 5 years follow-up. Finally, a bioinformatic analysis revealed the association between these two miRs and several targets implicated in prostate cancer initiation pathways.
AB - © 2018, Springer Nature B.V. Currently, microRNAs (miRs) represent great biomarkers in cancer due to their stability and their potential role in diagnosis, prognosis and therapy. This study aims to evaluate the expression levels of miRs-1260 and -1274a in prostate cancer (PC) samples and to identify their eventual targets by using bioinformatic analysis. In this project, we evaluated the expression status of miRs-1260 and -1274a in 86 PC patients and 19 controls by using real-time quantitative PCR and 2 −ΔΔCt method. Moreover, we retrieved validated and predicted targets of miRs from several datasets by using the “multiMir” R/Bioconductor package. We have found that miRs-1260 and -1274a were over-expressed in PC patients compared to controls (p < 1 × 10 −5 ). Moreover ROC curve for miRs-1260 and 1274a showed a good performance to distinguish between controls group and PC samples with an area under the ROC curve of 0.897 and 0.784 respectively. However, no significant association could be shown between these two miRs and clinical parameters such as PSA levels, Gleason score, tumor stage, D’Amico classification, lymph node metastasis statues, tumor recurrence, metastasis status and progression after a minimum of 5 years follow-up. Finally, a bioinformatic analysis revealed the association between these two miRs and several targets implicated in prostate cancer initiation pathways.
KW - Epigenetic
KW - MiR-1260
KW - MiR-1274a
KW - Over-expression
KW - Prostate cancer
KW - Tunisia
U2 - 10.1007/s11033-018-4399-x
DO - 10.1007/s11033-018-4399-x
M3 - Article
C2 - 30250996
SN - 0301-4851
VL - 45
SP - 2345
EP - 2358
JO - Molecular Biology Reports
JF - Molecular Biology Reports
ER -